Back to Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 2

Managing anemia in lymphoma and multiple myeloma

Authors Gunnar Birgegård

Published 11 April 2008 Volume 2008:4(2) Pages 527—539

DOI https://doi.org/10.2147/TCRM.S1351

Gunnar Birgegård

Department of Haematology, University Hospital, Uppsala, Sweden

Abstract: Anemia is common in cancer, and lymphoproliferative disease is no exception. Erythropoiesis-stimulating agents (ESA) have been used for renal anemia since 1986, and considerably later in cancer anemia. The first studies were published around 1993, but the use of ESA did not become common in cancer anemia until in the late 1990s. Cancer anemia is still under-treated. This review gives an overview of the use of ESA in hematologic malignancies. A background is given about this treatment in the cancer field generally. The pathophysiology of cancer anemia is described with special emphasis on the disturbances in iron metabolism. Functional iron deficiency has been shown to be both frequent and important as a hindrance for response to ESA treatment, and recent studies are reported in some detail, where the use of intravenous iron was shown to improve the response rate of ESA treatment.

Keywords: Epo, epoetin, ESA, cancer anemia, lymphoma, myeloma, lymphoproliferative disease

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

Safe and tolerable one-hour pamidronate infusion for multiple myeloma patients

Dimitrios Chantzichristos, Andréasson Björn, Johansson Peter

Therapeutics and Clinical Risk Management 2008, 4:1371-1374

Published Date: 5 December 2008

Brain abscess as a manifestation of spinal dermal sinus

Parisa Emami-Naeini, Ali Mahdavi, Hamed Ahmadi, Nima Baradaran, Farideh Nejat

Therapeutics and Clinical Risk Management 2008, 4:1143-1147

Published Date: 10 October 2008

Pharmacological management of acute bronchiolitis

Melvin Wright, Charles J Mullett, Giovanni Piedimonte

Therapeutics and Clinical Risk Management 2008, 4:895-903

Published Date: 10 October 2008

“One pill, once daily”: what clinicians need to know about Atripla™

Patrick G Clay, Tracey AH Taylor, Alan G Glaros, MaryPeace McRae, Charlott Williams, et al

Therapeutics and Clinical Risk Management 2008, 4:291-302

Published Date: 11 April 2008

Update on the treatment of ankylosing spondylitis

Walter P Maksymowych

Therapeutics and Clinical Risk Management 2007, 3:1125-1133

Published Date: 15 January 2008

Review of thalidomide in the treatment of newly diagnosed multiple myeloma

Federica Cavallo, Mario Boccadoro, Antonio Palumbo

Therapeutics and Clinical Risk Management 2007, 3:543-552

Published Date: 15 September 2007

A review of rabeprazole in the treatment of acid-related diseases

Fabio Pace, Stefano Pallotta, Stefania Casalini, Gabriele Bianchi Porro

Therapeutics and Clinical Risk Management 2007, 3:363-379

Published Date: 15 July 2007

Effect of patient-specific factors on weekly warfarin dose

Heather P Whitley, Joli D Fermo, Elinor CG Chumney, Walter Adam Brzezinski

Therapeutics and Clinical Risk Management 2007, 3:499-504

Published Date: 15 July 2007